Here are the DEF 14A proxy statements from ANI Pharmaceuticals, Inc. (ANIP) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow ANIP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANIP filings page.
ANI Pharmaceuticals, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on May 21, 2026. Holders of 22,750,198 shares of Common Stock and 10,864 shares of Class C Special Stock as of March 23, 2026 can vote one vote per share.
Stockholders will elect seven directors, ratify Ernst & Young LLP as auditor for 2026, cast advisory votes on executive compensation and its future frequency, and approve an Amended and Restated 2022 Stock Incentive Plan. The proxy highlights record 2025 net revenues of $883.4 million, up 43.8%, and adjusted non‑GAAP EBITDA of $229.8 million, up 47.3%, driven by strong Rare Disease and Generics performance.